AI Insight
The ACHIEVE-4 trial evaluated the cardiovascular safety of orforglipron, an oral medication, compared to insulin glargine in adults with type 2 diabetes at elevated cardiovascular risk. The study demonstrated that orforglipron was non-inferior to insulin glargine for major adverse cardiovascular events (MACE-4), meeting its primary safety endpoint. Orforglipron showed fewer episodes of clinically significant hypoglycemia than insulin glargine, though gastrointestinal side effects were more common and represented the primary reason for treatment discontinuation.
Why it matters
This research establishes orforglipron as a potential once-daily oral treatment alternative to injectable insulin for managing type 2 diabetes in patients with cardiovascular risk factors. The oral administration route and lower hypoglycemia risk could improve treatment adherence and patient quality of life while maintaining cardiovascular safety.
Understand the Science
In people with type 2 diabetes at increased cardiovascular risk, the cardiovascular safety of orforglipron was confirmed by demonstrating non-inferiority to insulin glargine for MACE-4. Gastrointestinal adverse events were the most frequent adverse event and most common reason for orforglipron treatment discontinuation with orforglipron, while clinically significant hypoglycaemia occurred less frequently with orforglipron than with insulin glargine. These findings support orforglipron as a potential once-daily, oral treatment option with established cardiovascular safety in people with type 2 diabetes and increased cardiovascular risk.